BELLUS Health (NASDAQ:BLU – Get Rating) and GH Research (NASDAQ:GHRS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
Profitability
This table compares BELLUS Health and GH Research’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BELLUS Health | -475,500.00% | -22.69% | -21.48% |
| GH Research | N/A | -11.37% | -11.21% |
Earnings and Valuation
This table compares BELLUS Health and GH Research’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BELLUS Health | $20,000.00 | 91,327.47 | -$76.08 million | ($0.65) | -22.20 |
| GH Research | N/A | N/A | -$22.46 million | ($0.43) | -18.49 |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for BELLUS Health and GH Research, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BELLUS Health | 0 | 3 | 2 | 0 | 2.40 |
| GH Research | 0 | 0 | 4 | 0 | 3.00 |
BELLUS Health currently has a consensus target price of $16.50, indicating a potential upside of 14.35%. GH Research has a consensus target price of $48.00, indicating a potential upside of 503.77%. Given GH Research’s stronger consensus rating and higher possible upside, analysts plainly believe GH Research is more favorable than BELLUS Health.
Risk & Volatility
BELLUS Health has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, GH Research has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
Institutional and Insider Ownership
90.1% of BELLUS Health shares are owned by institutional investors. Comparatively, 62.6% of GH Research shares are owned by institutional investors. 24.2% of BELLUS Health shares are owned by company insiders. Comparatively, 41.6% of GH Research shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
GH Research beats BELLUS Health on 11 of the 13 factors compared between the two stocks.
About BELLUS Health
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
About GH Research
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.
